Alembic Ltd is one of the India's most experienced manufactures of bulk drugs and pharmaceuticals formulation in human and animal healthcare. They are the first pharmaceutical company in India to cross 100 years of operations. They are in the business of improving the quality of life and healthcare in over 75 countries around the world.

The company is a ISO-9002 and ISO-14001 certified company with manufacturing practices and facilities that conform to WHO-GMP guidelines. They manufacture pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations. They are having their manufacturing facilities at Vadodara in Gujarat and Solan in Himachal Pradesh.

Alembic Ltd was formally created and deployed as a legal entity in the year 1907 with the name Alembic Chemical Works Co Ltd in Vadodara to manufacture tinctures and alcohol. They Started to manufacture cough syrup, vitamins, tonics and sulphur durgs in the year 1940. In the year 1961, they inaugrated the Pencillin Palnt. In the year 1968, they started to manufacture Streptomycin.

In the 1971, they manufactured Erythromycin using expertise from Eli Lilly, USA and in the year 1972, they formally introduced Althrocin, a brand of Erythromycin. In the year 1997, Althrocin become top selling brand in India. In the year 2001, they started to manufacture Cephalosporin C. In June 2001, the company formed a wholly owned subsidiary company named Alembic Europe Pvt Ltd in UK.

In the year 2005, the company has formally introduced ZERO, a new generation, no calories, Sucralose Based Sugar Substitute which gave entry for the company into the high-growth lifestyle OTC product segment. In May 2005, the generic alliances and API division were merged to form an independent SBU.

The company has created and deployed a formulation manufacturing facility at Baddi in Himachal Pradesh with a production capacity 900 million tablets and 600 million liquid oral bottles annually. During the year 2005-06, the company has increased the installed capacity of Tablets & Capsules and Oral Preparation & Ointments by 595 Million Nos and 720 MT respectively.

During the year 2005-06, the company executed a strategic acquisition of API Plant at Karakhadi in Vadodara. In the year 2007, the company executed a strategic acquisition of the Non-Oncology Business of Dabur Pharma Ltd. Also in the same year, they broadened its footprint operations into into a licensing agreement for its Novel Drug Delivery Platform for Keppra XR with UCB Belgium. During the year 2007-08, the company executed a strategic acquisition of the API manufacturing facility of Nirayu Pvt Ltd at Panelav near Vododara.